A Real-world Study of Selinexor-based Regimens for Treatment of Non-Hodgkin Lymphoma

Shanghai Jiao Tong University

Status: Enrolling

Conditions: T Cell Lymphoma; DLBCL; Lymphoma

Treatments: Drug: Selinexor

Study type: Observational

Funder types: Other

Identifiers

NCT05852028

RJ-XLYM-001

Details and patient eligibility

About

This study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with Non-Hodgkin lymphoma

Full description

this study aims to observe and explore the efficacy and safety of selinexor-based regimen in patients with DLBCL or T cell lymphoma. This study is a non-interventional real world, observational study and all registered data are collected from real clinical practice cases. The medical data includes patient demographic, tumor characteristics, laboratory examination, history of treatments, adverse reactions, efficacy results and possible prognostic factors.

Enrollment: 250 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Know and voluntarily sign the Informed Consent Form (ICF)
• Clinically confirmed DLBCL, T or NK cell lymphoma
• Patients with DLBCL or T or NK cell lymphoma who have used selinexor-based therapy in the past 3 months are included
• Cooperate with clinical diagnosis and treatment management, and provide disease-related past medical history materials

Exclusion criteria

• Previously received selinexor
• Poor patient compliance
• physicians evaluate that patients are not suitable for enrollment

Trial design

250 participants in 1 patient group

selinexor-based regimens

Description:

This study is a real-world study to explore the safety and efficacy of selinexor-based therapy in patients with lymphoma. It is planned to enroll 250 patients with lymphoma, including 150 patients with diffuse large B-cell lymphoma and 100 patients with peripheral T and NK/T-cell lymphoma.

Treatment:

Drug: Selinexor